K S Gordon1, A Manhapra2, S Crystal3, J Dziura4, E J Edelman5, M Skanderson6, R D Kerns7, A C Justice8, J Tate9, W C Becker9. 1. VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States. Electronic address: kirsha.gordon2@va.gov. 2. Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States; Integrative Pain Recovery Service, Hampton VA Medical Center, Hampton, VA, United States; Departments of Physical Medicine & Rehabilitation and Psychiatry, Eastern Virginia Medical School, Norfolk, VA, United States. 3. Rutgers University, New Brunswick, NJ, United States. 4. Yale School of Public Health, New Haven, CT, United States. 5. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States. 6. VA Connecticut Healthcare System, West Haven, CT, United States. 7. Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States; Department of Neurology, Yale School of Medicine, New Haven, CT, United States. 8. VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States. 9. VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.
Abstract
BACKGROUND: While the relationship between long-term opioid therapy (LTOT) dose and overdose is well-established, LTOT's association with all-cause mortality is less understood, especially among people living with HIV (PLWH). There is also limited information regarding the association of LTOT cessation or interruption with mortality. METHODS: Among PLWH and matched uninfected male veterans in care, we identified those who initiated LTOT. Using time-updated cox regression, we examined the association between all-cause mortality, unnatural death, and overdose, and opioid use categorized as 1-20 (reference group), 21-50, 51-90, and ≥ 91 mg morphine equivalent daily dose (MEDD). RESULTS: There were 22,996 patients on LTOT, 6,578 (29 %) PLWH and 16,418 (71 %) uninfected. Among 5,222 (23 %) deaths, 12 % were unnatural deaths and 6 % overdoses. MEDD was associated with risk of all 3 outcomes; compared to patients on 1-20 mg MEDD, adjusted risk for all-cause mortality monotonically increased (Hazard Ratios (HR) [95 % CI] for 21-50 mg MEDD = 1.36 [1.21, 1.52], 51-90 mg MEDD = 2.06 [1.82, 2.35], and ≥ 91 mg MEDD = 3.03 [2.71, 3.39]). Similar results were seen in models stratified by HIV. LTOT interruption was also associated with all-cause, unnatural, and overdose mortality (HR [95 % CI] 2.30 [2.09, 2.53], 1.47 [1.13, 1.91] and 1.52 [1.04, 2.23], respectively). CONCLUSIONS: Among PLWH and uninfected patients on LTOT we observed a strong dose-response relationship with all 3 mortality outcomes. Opioid risk mitigation approaches should be expanded to address the potential effects of higher dose on all-cause mortality in addition to unnatural and overdose fatalities.
BACKGROUND: While the relationship between long-term opioid therapy (LTOT) dose and overdose is well-established, LTOT's association with all-cause mortality is less understood, especially among people living with HIV (PLWH). There is also limited information regarding the association of LTOT cessation or interruption with mortality. METHODS: Among PLWH and matched uninfected male veterans in care, we identified those who initiated LTOT. Using time-updated cox regression, we examined the association between all-cause mortality, unnatural death, and overdose, and opioid use categorized as 1-20 (reference group), 21-50, 51-90, and ≥ 91 mg morphine equivalent daily dose (MEDD). RESULTS: There were 22,996 patients on LTOT, 6,578 (29 %) PLWH and 16,418 (71 %) uninfected. Among 5,222 (23 %) deaths, 12 % were unnatural deaths and 6 % overdoses. MEDD was associated with risk of all 3 outcomes; compared to patients on 1-20 mg MEDD, adjusted risk for all-cause mortality monotonically increased (Hazard Ratios (HR) [95 % CI] for 21-50 mg MEDD = 1.36 [1.21, 1.52], 51-90 mg MEDD = 2.06 [1.82, 2.35], and ≥ 91 mg MEDD = 3.03 [2.71, 3.39]). Similar results were seen in models stratified by HIV. LTOT interruption was also associated with all-cause, unnatural, and overdosemortality (HR [95 % CI] 2.30 [2.09, 2.53], 1.47 [1.13, 1.91] and 1.52 [1.04, 2.23], respectively). CONCLUSIONS: Among PLWH and uninfected patients on LTOT we observed a strong dose-response relationship with all 3 mortality outcomes. Opioid risk mitigation approaches should be expanded to address the potential effects of higher dose on all-cause mortality in addition to unnatural and overdose fatalities.
Authors: Kevin L Kraemer; Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Adam J Gordon; Jonathan Robbins; Susan Zickmund; Kendall Bryant; P Todd Korthuis Journal: J Subst Abuse Treat Date: 2019-05-07
Authors: C Richard Chapman; David L Lipschitz; Martin S Angst; Roger Chou; Richard C Denisco; Gary W Donaldson; Perry G Fine; Kathleen M Foley; Rollin M Gallagher; Aaron M Gilson; J David Haddox; Susan D Horn; Charles E Inturrisi; Susan S Jick; Arthur G Lipman; John D Loeser; Meredith Noble; Linda Porter; Michael C Rowbotham; Karen M Schoelles; Dennis C Turk; Ernest Volinn; Michael R Von Korff; Lynn R Webster; Constance M Weisner Journal: J Pain Date: 2010-04-28 Impact factor: 5.820
Authors: Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi Journal: JAMA Date: 2008-12-10 Impact factor: 56.272
Authors: Patrick D Quinn; Zheng Chang; Matthew J Bair; Martin E Rickert; Robert D Gibbons; Kurt Kroenke; Brian M D'Onofrio Journal: Pain Date: 2022-04-01 Impact factor: 7.926